Transaction DateRecipientSharesTypePriceValue
4th January 2021Mark Alan Goldberg3,452Grant/award etc.$4.02$13,877.04
24th December 2020Mark Alan Goldberg5,455Open or private sale$125.00$681,875.00
24th December 2020Mark Alan Goldberg5,455Exercise of derivative$28.15$153,558.25
18th December 2020Mark Alan Goldberg5,454Exercise of derivative$28.15$153,530.10
18th December 2020Mark Alan Goldberg5,454Open or private sale$120.00$654,480.00
17th December 2020Charles A Jr Rowland10,909Exercise of derivative$19.53$213,052.77
17th December 2020Charles A Jr Rowland10,909Open or private sale$117.82$1,285,298.38
14th December 2020Marion Dorsch4,600Exercise of derivative$37.11$170,706.00
14th December 2020Jeffrey W. Albers5,000Open or private sale$119.18$595,900.00
14th December 2020Jeffrey W. Albers5,000Exercise of derivative$8.80$44,000.00
Blueprint Medicines
Blueprint Medicines logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Blueprint Medicines Corp. focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy in 2008.


Ticker: BPMC
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1597264
Employees: 383
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $289 M (0%)
Inventory, Net: $4 M (0%)
Assets, Current: $568 M (9%)
Property, Plant and Equipment, Net: $37 M (0%)
Other Assets, Noncurrent: $8 M (-18%)
Assets: $817 M (15%)
Accounts Payable, Current: $6 M (16%)
Accrued Liabilities, Current: $84 M (0%)
Liabilities, Current: $105 M (-1%)
Other Liabilities, Noncurrent: $9 M (9%)
Liabilities: $236 M (-2%)
Common Stock, Value, Issued: $54 Th (10%)
Common Stock, Shares, Issued: $54 M (10%)
Retained Earnings (Accumulated Deficit): $1 B (24%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 M (-55%)
Stockholders' Equity (Parent): $581 M (0%)
Liabilities and Equity: $817 M (15%)
Cost of Revenue: $127 Th (-15%)
Research and Development: $91 M (-48%)
Other Income, net: $2 M (-63%)